You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib

Chung, Caroline; Dawson, Laura A.; Joshua, Anthony M.; Brade, Anthony M.

Anti-Cancer Drugs:
doi: 10.1097/CAD.0b013e328333d679
Case Reports
Abstract

Small molecule tyrosine kinase inhibitors are rapidly being integrated into the management of cancer. This is the first report of sorafenib and sunitinib, both small molecule tyrosine kinase inhibitors of vascular endothelial growth factor and platelet-derived growth factor receptors, triggering radiation recall dermatitis. The pathophysiology of radiation recall is poorly understood, and several possible mechanisms have been proposed. The clinical presentations of these two cases were consistent with one hypothesized mechanism of radiation recall, an idiosyncratic drug hypersensitivity reaction.

Author Information

Princess Margaret Hospital, Toronto, Ontario, Canada

Correspondence to Dr Anthony Brade, FRCPC, MD, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario, Canada M5G 2M9

Tel: +1 416 946 6513; fax: +1 416 946 2227; e-mail: anthony.brade@rmp.uhn.on.ca

Received 3 August 2009 Revised form accepted 5 October 2009

© 2010 Lippincott Williams & Wilkins, Inc.